TRML: Q2 delivered robust sales growth, higher margins, and new medical partnerships, sustaining momentum
· Issued by Trainimal AB
Q2 saw strong revenue growth of 27.3% year-over-year, with positive EBITDA and net profit. Subscription and supplement sales increased, gross margin improved, and a new medical weight loss partnership was launched. Positive trends are expected to continue.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
